Nanotechnology in antimicrobial photodynamic inactivation

Sami Nazzal, Chueh Pin Chen, Tsuimin Tsai

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) and photodynamic inactivation (PDI) are technologies that utilize visible light and photosensitizers (PS) to inactivate cells. PDT is currently in use for the treatment of several types of tumors. Although cancer has been successfully treated with PS and light, antimicrobial PDI is emerging as a new treatment modality for bacterial infections due to its effectiveness and less likelihood of inducing bacterial resistance. Resistance to therapy is in part due to the ability of the organisms to form a biofilm, which provides a microenvironment that protects the microorganism from antibiotics and attack by the host's immune system. In vitro, PDI nonetheless was shown to be effective against Gram-negative and Gram-positive bacteria. When used in-vivo however, several factors were shown to influence and diminish the effectiveness of PDI, such as aggregation of PS and plasma protein binding. To circumvent these factors, different nanotechnology platforms were used to enhance the photodynamic inactivation efficacy, such as liposomes, micelles and nanoparticles, by reducing the PS aggregation and albumin binding to the PS. In general, studies have shown that photodynamic inactivation efficacy could be enhanced when suitable nanocarriers are used to deliver the PS.

Original languageEnglish
JournalJournal of Food and Drug Analysis
Volume19
Issue number4
Publication statusPublished - Dec 2011

Fingerprint

nanotechnology
Nanotechnology
Photosensitizing Agents
inactivation
anti-infective agents
Photochemotherapy
therapeutics
Organism Forms
Light
neoplasms
protein binding
Gram-Positive Bacteria
Micelles
micelles
nanoparticles
Biofilms
Gram-positive bacteria
bacterial infections
Bacterial Infections
Protein Binding

Keywords

  • Liposome
  • Micelle
  • Nanoparticles
  • Photodynamic inactivation

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Nanotechnology in antimicrobial photodynamic inactivation. / Nazzal, Sami; Chen, Chueh Pin; Tsai, Tsuimin.

In: Journal of Food and Drug Analysis, Vol. 19, No. 4, 12.2011.

Research output: Contribution to journalArticle

Nazzal, Sami ; Chen, Chueh Pin ; Tsai, Tsuimin. / Nanotechnology in antimicrobial photodynamic inactivation. In: Journal of Food and Drug Analysis. 2011 ; Vol. 19, No. 4.
@article{11ab616ae952479baba775aabfa1e639,
title = "Nanotechnology in antimicrobial photodynamic inactivation",
abstract = "Photodynamic therapy (PDT) and photodynamic inactivation (PDI) are technologies that utilize visible light and photosensitizers (PS) to inactivate cells. PDT is currently in use for the treatment of several types of tumors. Although cancer has been successfully treated with PS and light, antimicrobial PDI is emerging as a new treatment modality for bacterial infections due to its effectiveness and less likelihood of inducing bacterial resistance. Resistance to therapy is in part due to the ability of the organisms to form a biofilm, which provides a microenvironment that protects the microorganism from antibiotics and attack by the host's immune system. In vitro, PDI nonetheless was shown to be effective against Gram-negative and Gram-positive bacteria. When used in-vivo however, several factors were shown to influence and diminish the effectiveness of PDI, such as aggregation of PS and plasma protein binding. To circumvent these factors, different nanotechnology platforms were used to enhance the photodynamic inactivation efficacy, such as liposomes, micelles and nanoparticles, by reducing the PS aggregation and albumin binding to the PS. In general, studies have shown that photodynamic inactivation efficacy could be enhanced when suitable nanocarriers are used to deliver the PS.",
keywords = "Liposome, Micelle, Nanoparticles, Photodynamic inactivation",
author = "Sami Nazzal and Chen, {Chueh Pin} and Tsuimin Tsai",
year = "2011",
month = "12",
language = "English",
volume = "19",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - Nanotechnology in antimicrobial photodynamic inactivation

AU - Nazzal, Sami

AU - Chen, Chueh Pin

AU - Tsai, Tsuimin

PY - 2011/12

Y1 - 2011/12

N2 - Photodynamic therapy (PDT) and photodynamic inactivation (PDI) are technologies that utilize visible light and photosensitizers (PS) to inactivate cells. PDT is currently in use for the treatment of several types of tumors. Although cancer has been successfully treated with PS and light, antimicrobial PDI is emerging as a new treatment modality for bacterial infections due to its effectiveness and less likelihood of inducing bacterial resistance. Resistance to therapy is in part due to the ability of the organisms to form a biofilm, which provides a microenvironment that protects the microorganism from antibiotics and attack by the host's immune system. In vitro, PDI nonetheless was shown to be effective against Gram-negative and Gram-positive bacteria. When used in-vivo however, several factors were shown to influence and diminish the effectiveness of PDI, such as aggregation of PS and plasma protein binding. To circumvent these factors, different nanotechnology platforms were used to enhance the photodynamic inactivation efficacy, such as liposomes, micelles and nanoparticles, by reducing the PS aggregation and albumin binding to the PS. In general, studies have shown that photodynamic inactivation efficacy could be enhanced when suitable nanocarriers are used to deliver the PS.

AB - Photodynamic therapy (PDT) and photodynamic inactivation (PDI) are technologies that utilize visible light and photosensitizers (PS) to inactivate cells. PDT is currently in use for the treatment of several types of tumors. Although cancer has been successfully treated with PS and light, antimicrobial PDI is emerging as a new treatment modality for bacterial infections due to its effectiveness and less likelihood of inducing bacterial resistance. Resistance to therapy is in part due to the ability of the organisms to form a biofilm, which provides a microenvironment that protects the microorganism from antibiotics and attack by the host's immune system. In vitro, PDI nonetheless was shown to be effective against Gram-negative and Gram-positive bacteria. When used in-vivo however, several factors were shown to influence and diminish the effectiveness of PDI, such as aggregation of PS and plasma protein binding. To circumvent these factors, different nanotechnology platforms were used to enhance the photodynamic inactivation efficacy, such as liposomes, micelles and nanoparticles, by reducing the PS aggregation and albumin binding to the PS. In general, studies have shown that photodynamic inactivation efficacy could be enhanced when suitable nanocarriers are used to deliver the PS.

KW - Liposome

KW - Micelle

KW - Nanoparticles

KW - Photodynamic inactivation

UR - http://www.scopus.com/inward/record.url?scp=84863118940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863118940&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84863118940

VL - 19

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 4

ER -